Cargando…

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples

With the development of ever more radiopharmaceuticals suitable for theranostic applications, translation of novel compounds from the preclinical stage towards clinical application becomes a bottleneck for the advances in Nuclear Medicine. This review article summarizes the current regulatory framew...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolenc Peitl, Petra, Rangger, Christine, Garnuszek, Piotr, Mikolajczak, Renata, Hubalewska‐Dydejczyk, Alicja, Maina, Theodosia, Erba, Paola, Decristoforo, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Special Issue Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767129/ https://www.ncbi.nlm.nih.gov/pubmed/30741441 http://dx.doi.org/10.1002/jlcr.3712

Ejemplares similares

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
por: von Guggenberg, Elisabeth, et al.
Publicado: (2021)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
por: Novak, Doroteja, et al.
Publicado: (2023)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

EANM guideline on the validation of analytical methods for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2020)

Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals
por: Koziorowski, J., et al.
Publicado: (2016)

Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
por: Korde, Aruna, et al.
Publicado: (2022)

Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2021)

Are we “preparing” radiopharmaceuticals?
por: Decristoforo, Clemens, et al.
Publicado: (2016)

EANM guideline on quality risk management for radiopharmaceuticals
por: Gillings, Nic, et al.
Publicado: (2022)

Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
por: Elsinga, Philip, et al.
Publicado: (2010)

Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
por: Todde, S., et al.
Publicado: (2017)

Clickable Radiocomplexes With Trivalent Radiometals for Cancer Theranostics: In vitro and in vivo Studies
por: D'Onofrio, Alice, et al.
Publicado: (2021)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
por: Barca, Cristina, et al.
Publicado: (2021)

Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers
por: D’Onofrio, Alice, et al.
Publicado: (2022)

Imaging of inflamed carotid artery atherosclerotic plaques with the use of (99m)Tc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients
por: Opalinska, Marta, et al.
Publicado: (2012)

Exendin‐4 analogs in insulinoma theranostics
por: Jansen, Tom.J.P., et al.
Publicado: (2019)

How far are we from understanding the genetic basis of Hashimoto’s thyroiditis?
por: Hubalewska-Dydejczyk, Alicja
Publicado: (2013)

Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue
por: Pfister, Joachim, et al.
Publicado: (2015)

Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
por: Mikolajczak, R., et al.
Publicado: (2021)

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor
por: Lipiński, Piotr F. J., et al.
Publicado: (2018)

US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations
por: Schwarz, Sally W., et al.
Publicado: (2019)

The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?
por: Peñuelas, Iván, et al.
Publicado: (2019)

Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology
por: Rahmim, Arman, et al.
Publicado: (2022)

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
por: Fersing, Cyril, et al.
Publicado: (2022)

Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
por: Carter, Korey P., et al.
Publicado: (2020)

Radiopharmaceuticals as Novel Immune System Tracers
por: Ridge, Natalie A., et al.
Publicado: (2022)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)
por: Jalilian, Amirreza, et al.
Publicado: (2023)

Instant kit preparation of (68)Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [(68)Ga]Ga-DATA-TOC
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_16hrki9uhda4fr29hsi6mpfv31